Nondialysis chronic kidney disease in 2011: Progression, prediction, populations and possibilities

Nature Reviews Nephrology

Volumn 8, Issue 2, 2012, Pages 70-72

  Levin, Adeera ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BARDOXOLONE; CYSTATIN C; EZETIMIBE; FIBROBLAST GROWTH FACTOR 23; SIMVASTATIN; UROKINASE RECEPTOR;

ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG MECHANISM; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HUMAN; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; PLASMAPHERESIS; PODOCYTE; PREDICTION; PRIORITY JOURNAL; REVIEW;

ANIMALS; ATHEROSCLEROSIS; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; HYPOLIPIDEMIC AGENTS; KIDNEY FAILURE, CHRONIC; PROGNOSIS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 84856409470     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.195     Document Type: Review

References (10)

1. Peralta, C. A. et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 305, 1545-1552 (2011).
2. Friedman, D. J., Kozlitina, J., Genovese, G., Jog, P. & Pollak, M.R. Population-based risk assessment of APOL1 on renal disease. J. Am. Soc. Nephrol. 22, 2098-2105 (2011).
3. Wei, C. et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat. Med. 17, 952-960 (2011).
4. Tangri, N. et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA 305, 1553-1557 (2011).
5. Perkins, R. M. et al. GFR decline and mortality risk among patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 6, 1879-1886 (2011).
6. Astor, B. C. et al. and the Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 79, 1331-1340 (2011).
7. Levey, A. S. et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 80, 17-28 (2011).
8. Isakova, T. et al. for the Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305, 2432-2439 (2011).
9. Pergola, P. E. et al. for the BEAM Study Investigators. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 365, 327-336 (2011).
10. Baigent, C. et al. on behalf of the SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377, 2181-2192 (2011).